Evotec SE (ADR)
General ticker "EVO" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $1.4B (TTM average)
Evotec SE (ADR) does not follow the US Stock Market performance with the rate: -13.9%.
Estimated limits based on current volatility of 1.7%: low 3.19$, high 3.30$
Factors to consider:
- Total employees count: 203 as of 2007
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.13$, 4.51$]
- 2026-12-31 to 2027-12-31 estimated range: [2.15$, 4.52$]
Financial Metrics affecting the EVO estimates:
- Positive: with PPE of -11.3 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -0.98 <= 0.07
- Positive: 42.60 < Shareholder equity ratio, % of 45.75 <= 64.25
- Positive: Investing cash flow per share per price, % of 17.32 > -0.65
- Positive: Inventory ratio change, % of -0.43 <= 0
Short-term EVO quotes
Long-term EVO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | €781.43MM | €796.97MM | €757.26MM |
| Operating Expenses | €828.93MM | €939.49MM | €892.57MM |
| Operating Income | €-47.51MM | €-142.52MM | €-135.31MM |
| Non-Operating Income | €-33.09MM | €-51.45MM | €12.00MM |
| Interest Expense | €11.74MM | €11.70MM | €13.87MM |
| R&D Expense | €68.53MM | €50.86MM | €74.33MM |
| Income(Loss) | €-80.59MM | €-193.98MM | €-123.31MM |
| Taxes | €3.32MM | €2.10MM | €-23.88MM |
| Profit(Loss)* | €-83.91MM | €-196.08MM | €-99.43MM |
| Stockholders Equity | €1,119.91MM | €952.52MM | €813.36MM |
| Inventory | €30.89MM | €31.12MM | €29.30MM |
| Assets | €2,252.47MM | €1,912.50MM | €1,778.00MM |
| Operating Cash Flow | €36.44MM | €18.22MM | €-9.06MM |
| Capital expenditure | €216.00MM | €132.24MM | €69.68MM |
| Investing Cash Flow | €-13.29MM | €-71.19MM | €159.86MM |
| Financing Cash Flow | €71.96MM | €-161.42MM | €-30.93MM |
| Earnings Per Share** | €-0.24 | €-0.55 | €-0.28 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.